Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.57 |
| ▸ | BTK | Q06187 | 5/20 | 0.57 |
| ▸ | SRC | P12931 | 12/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 9/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.51 |
| ▸ | ABL1 | P00519 | 7/20 | 0.51 |
| ▸ | HCK | P08631 | 7/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.51 |
| ▸ | MTOR | P42345 | 7/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 7/20 | 0.51 |
| ▸ | PRKDC | P78527 | 7/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 6/20 | 0.51 |
| ▸ | LCK | P06239 | 4/20 | 0.51 |
| ▸ | TEK | Q02763 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | LYN | P07948 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5812688 | 0.89 | EGFR (0.44) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL4826519 | 0.89 | FGFR1 (0.59) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL4819029 | 0.88 | LCK (0.65) | EGFRBTKSRCKDRLCK | |
| SCHEMBL4819033 | 0.88 | LCK (0.65) | EGFRBTKSRCKDRLCK | |
| SCHEMBL4828237 | 0.84 | SRC (0.57) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL4822127 | 0.84 | SRC (0.57) | EGFRBTKSRCKDRPIK3CD | |
| SCHEMBL4825795 | 0.83 | SRC (0.61) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL6272921 | 0.83 | EGFR (0.40) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL4826841 | 0.79 | SRC (0.57) | EGFRBTKSRCFGFR1KDR | |
| SCHEMBL4827168 | 0.78 | BTK (0.55) | EGFRBTKSRCKDRPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1379528-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH (DE) | 2005-12-07 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20050008640-A1 | Method of treating transplant rejection | ABBOTT LABORATORIES | 2005-01-13 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| EP-1379528-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GmbH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| WO-2002076986-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050008640-A1 | Method of treating transplant rejection | LCK, ZAP70, FYN | EGFR 818/4885BTK 42/4885SRC 46/4885 |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | EGFR 1992/4885BTK 1399/4885SRC 2167/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | EGFR 2229/4885BTK 1020/4885SRC 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.